Taisho Pharmaceutical Holdings Co., Ltd. (TAISF)

57.85 0.00 (0.00%) At close: 01:16PM EST

Taisho Pharmaceutical Holdings Co., Ltd.

3-24-1 Takada
Toshima-ku
Tokyo 170-8655
Japan
81 3 3985 2020
https://www.taisho-holdings.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 8,784

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Akira Uehara	CEO & Representative Director	767.72k	N/A	1941
Mr. Shigeru Uehara	Executive VP & Director	835.66k	N/A	N/A
Shinichi Tanaka	General Manager of Corporate Communications	N/A	N/A	N/A
Mr. Ken Uehara	MD & Executive Director	713.37k	N/A	N/A
Mr. Tetsu Watanabe	Executive Director	N/A	N/A	N/A
Mr. Jun Kuroda	Executive VP & Director	N/A	N/A	1958

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. Further it provides Clarith, a macrolide antibiotic; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products, as well as engages in real estate leasing, management, possession, and operation. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is based in Tokyo, Japan.

Corporate Governance

Taisho Pharmaceutical Holdings Co., Ltd.’s ISS Governance QualityScore as of December 1, 2023 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.